Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on 'Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?'

MLA

Dorothy Cheuk-Yan Yiu, et al. “Dipeptidyl Peptidase-4 Inhibitors Are Associated with Improved Survival of Patients with Diabetes Mellitus and Hepatocellular Carcinoma Receiving Immunotherapy: Letter to the Editor on ‘Statin and Aspirin for Chemoprevention of Hepatocellular Carcinoma: Time to Use or Wait Further?’” Clinical and Molecular Hepatology, vol. 30, no. 4, Oct. 2024, pp. 970–73. EBSCOhost, https://doi.org/10.3350/cmh.2024.0280.

APA

Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, & Terry Cheuk-Fung Yip. (2024). Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?” Clinical and Molecular Hepatology, 30(4), 970–973. https://doi.org/10.3350/cmh.2024.0280

Chicago

Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, and Terry Cheuk-Fung Yip. 2024. “Dipeptidyl Peptidase-4 Inhibitors Are Associated with Improved Survival of Patients with Diabetes Mellitus and Hepatocellular Carcinoma Receiving Immunotherapy: Letter to the Editor on ‘Statin and Aspirin for Chemoprevention of Hepatocellular Carcinoma: Time to Use or Wait Further?’” Clinical and Molecular Hepatology 30 (4): 970–73. doi:10.3350/cmh.2024.0280.